Literature DB >> 19169812

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines.

Alan Mackay1, Narinder Tamber, Kerry Fenwick, Marjan Iravani, Anita Grigoriadis, Tim Dexter, Christopher J Lord, Jorge S Reis-Filho, Alan Ashworth.   

Abstract

Tumour cell lines derived from breast cancer patients constitute one of the cornerstones of breast cancer research. To characterise breast cancer cell lines at the genetic level, we have developed a full tiling path bacterial artificial chromosome (BAC) array collection for comparative genomic hybridisation (aCGH). This aCGH BAC collection covers 98% of the entire human genome at a resolution of 40-60 kbp. We have used this platform alongside an in-house produced 17 K cDNA microarray set to characterise the genetic and transcriptomic profiles of 24 breast cancer cell lines, as well as cell types derived from non-diseased breast. We demonstrate that breast cancer cell lines have genomic and transcriptomic features that recapitulate those of primary breast cancers and can be reliably subclassified into basal-like and luminal subgroups. By overlaying aCGH and transcriptomic data, we have identified 753 genes whose expression correlate with copy number; this list comprised numerous oncogenes recurrently amplified and overexpressed in breast cancer (e.g., HER2, MYC, CCND1 and AURKA). Finally, we demonstrate that although breast cancer cell lines have genomic features usually found in grade III breast cancers (i.e., gains of 1q, 8q and 20q), basal-like and luminal cell lines are characterised by distinct genomic aberrations.

Entities:  

Mesh:

Year:  2009        PMID: 19169812     DOI: 10.1007/s10549-008-0296-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

2.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Authors:  Sara Rodriguez-Acebes; Ian Proctor; Marco Loddo; Alex Wollenschlaeger; Mohammed Rashid; Mary Falzon; A Toby Prevost; Richard Sainsbury; Kai Stoeber; Gareth H Williams
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.

Authors:  Giuseppe Galletti; Matthew S Sung; Linda T Vahdat; Manish A Shah; Steven M Santana; Giuseppe Altavilla; Brian J Kirby; Paraskevi Giannakakou
Journal:  Lab Chip       Date:  2013-11-07       Impact factor: 6.799

4.  ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.

Authors:  Aurélie Thollet; Julie A Vendrell; Léa Payen; Sandra E Ghayad; Sabrina Ben Larbi; Evelyne Grisard; Colin Collins; Marie Villedieu; Pascale A Cohen
Journal:  Mol Cancer       Date:  2010-11-08       Impact factor: 27.401

5.  Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Authors:  Raphaëlle Duprez; Paul M Wilkerson; Magali Lacroix-Triki; Maryou B Lambros; Alan MacKay; Roger A'Hern; Arnaud Gauthier; Vidya Pawar; Pierre-Emanuel Colombo; Frances Daley; Rachael Natrajan; Eric Ward; Gaëtan MacGrogan; Flavie Arbion; Patrick Michenet; Britta Weigelt; Anne Vincent-Salomon; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2011-12-09       Impact factor: 7.996

6.  Functional characterization of the 19q12 amplicon in grade III breast cancers.

Authors:  Rachael Natrajan; Alan Mackay; Paul M Wilkerson; Maryou B Lambros; Daniel Wetterskog; Monica Arnedos; Kai-Keen Shiu; Felipe C Geyer; Anita Langerød; Bas Kreike; Fabien Reyal; Hugo M Horlings; Marc J van de Vijver; Jose Palacios; Britta Weigelt; Jorge S Reis-Filho
Journal:  Breast Cancer Res       Date:  2012-03-20       Impact factor: 6.466

7.  Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Authors:  Katumi Tsuji; Shigeto Kawauchi; Soichiro Saito; Tomoko Furuya; Kenzo Ikemoto; Motonao Nakao; Shigeru Yamamoto; Masaaki Oka; Takashi Hirano; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

8.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Authors:  N Turner; M B Lambros; H M Horlings; A Pearson; R Sharpe; R Natrajan; F C Geyer; M van Kouwenhove; B Kreike; A Mackay; A Ashworth; M J van de Vijver; J S Reis-Filho
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

9.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Authors:  Nicholas Turner; Alex Pearson; Rachel Sharpe; Maryou Lambros; Felipe Geyer; Maria A Lopez-Garcia; Rachael Natrajan; Caterina Marchio; Elizabeth Iorns; Alan Mackay; Cheryl Gillett; Anita Grigoriadis; Andrew Tutt; Jorge S Reis-Filho; Alan Ashworth
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

10.  Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

Authors:  John L McElwee; Sunish Mohanan; Obi L Griffith; Heike C Breuer; Lynne J Anguish; Brian D Cherrington; Ashley M Palmer; Louise R Howe; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Joe W Gray; Scott A Coonrod
Journal:  BMC Cancer       Date:  2012-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.